Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 1

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma

Authors Teru Hideshima, Noopur Raje, Paul G Richardson, Kenneth C Anderson

Published 8 February 2008 Volume 2008:4(1) Pages 129—136

DOI https://doi.org/10.2147/TCRM.S1445

Teru Hideshima1, Noopur Raje1,2, Paul G Richardson1, Kenneth C Anderson1

1Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute; 2Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA

Abstract: Lenalidomide (also known as Revlimid®, CC-5013) is an immunomodulatory derivative of thalidomide and has more potent anti-tumor and anti-inflammatory effects than thalidomide. The molecular mechanisms of anti-tumor activity of lenalidomide have been extensively studied in multiple myeloma (MM) both preclinical models and in clinical trials. Lenalidomide: directly triggers growth arrest and/or apoptosis of drug resistant MM cells; inhibits binding of MM cells to bone marrow (BM) extracellular matrix proteins and stromal cells; modulates cytokine secretion and inhibits angiogenesis in the BM milieu; and augments host anti-tumor immunity. Lenalidomide achieved responses in patients with relapsed refractory MM. Moreover, lenalidomide with dexamethasone (Dex) demonstrates more potent anti-MM activities than Dex both in vitro and in randomized phase III clinical trials. Specifically, the combination improved overall and extent of response, as well as prolonged time to progression and overall survival, resulting in FDA approval of lenalidomide with Dex for therapy MM relapsing after prior therapy.

Keywords: lenalidomide, dexamethasone, multiple myeloma

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

A review of topotecan in combination chemotherapy for advanced cervical cancer

Minoo Robati, David Holtz, Charles J Dunton

Therapeutics and Clinical Risk Management 2008, 4:213-218

Published Date: 8 February 2008

Editorial ||FREE PAPER||

Garry M Walsh

Therapeutics and Clinical Risk Management 2008, 4:0-0

Published Date: 8 February 2008

Why does the world need another rotavirus vaccine?

Richard L Ward, Monica M McNeal, A Duncan Steele

Therapeutics and Clinical Risk Management 2008, 4:49-63

Published Date: 8 February 2008

Anidulafungin in the treatment of invasive fungal infections

Kathryn Sabol, Tawanda Gumbo

Therapeutics and Clinical Risk Management 2008, 4:71-78

Published Date: 8 February 2008

Cannabinoids in the management of difficult to treat pain

Ethan B Russo

Therapeutics and Clinical Risk Management 2008, 4:245-259

Published Date: 8 February 2008